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Summary. There is increasing evidence that blood viscosity
and its major determinants (haematocrit, plasma viscosity
and fibrinogen) are associated with an increased risk of
incident cardiovascular events; however, their associations
with mortality are not established. We therefore studied the
associations of these variables with cardiovascular events
and total mortality in 1238 men and women aged 25–
64 years, followed for 13 years in the first North Glasgow
MONICA (MONItoring CArdiovascular disease) survey and
West of Scotland centres in the Scottish Heart Health Study.
After adjustment for age and sex, increasing whole blood
viscosity, plasma viscosity, haematocrit and fibrinogen
(analysed by both von Clauss and heat precipitation assays)
were significantly associated with mortality. Only the
association for fibrinogen (von Clauss assay) remained sig-
nificant after adjustment for major cardiovascular risk fac-
tors. We conclude that clottable fibrinogen may be
independently associated with mortality. However, the sig-
nificance of this association, and the extent to which vis-
cosity is associated with mortality, remain to be established
in larger studies and meta-analyses.
Keywords: viscosity, haematocrit, fibrinogen, mortality,
heart disease.
Whole-blood viscosity (a global measure of the intrinsic flow
resistance of blood in macrovessels) was shown to be a
potentially independent predictor of cardiovascular events
in a prospective study of a random population sample (Lowe
et al, 1997) and in a primary prevention trial of a statin for
coronary heart disease (Lowe et al, 2000), but not in
another prospective study of hospital-referred patients with
intermittent claudication (Smith et al, 1998). Recent meta-
analyses of prospective studies of the major haematological
determinants of whole-blood viscosity [haematocrit, plasma
viscosity, red cell aggregation as measured by the erythro-
cyte sedimentation rate (ESR), and plasma fibrinogen] found
that each was an independent predictor of cardiovascular
events, after adjustment for major cardiovascular risk
factors (Danesh et al, 2000a,b). While increased blood
viscosity might play a causal role in cardiovascular disease
(CVD), such as by promoting atherosclerosis (Lee et al,
1998), thrombosis or ischaemia (Lowe, 1994), this remains
to be established by randomized trials of blood viscosity
reduction (Lowe, 1998; Danesh et al, 2000a).
There is some evidence that increased viscosity may be
associated with symptomatic leg ischaemia (claudication),
independently of the extent of underlying atherosclerosis
(Lowe et al, 1993; Lee et al, 1996), and that reducing
fibrinogen and viscosity improves claudication (Meade et al,
2002). It is therefore possible that increased viscosity may
cause patients with stenotic arterial disease to present
earlier; however, such persons may not necessarily suffer
severe consequences of CVD, such as an increased mortality.
Only two recent studies have reported on the association of
viscosity with total mortality. Koenig et al (2000) reported a
significant, independent association of plasma viscosity
(whole blood viscosity was not measured) with mortality
in the prospective Augsburg MONICA cohort. Lowe et al
(2000) reported a significant association of calculated
whole-blood viscosity with mortality in the West of Scotland
Coronary Prevention Study; however, only fibrinogen
remained associated with mortality after adjustment for
baseline CVD and classic cardiovascular risk factors.
We therefore report the association of blood viscosity
and its major determinants (haematocrit, viscosity and
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fibrinogen) with total mortality at 13 years follow-up of the
first North Glasgow MONICA (MONItoring CArdiovascular
disease) study and West of Scotland centres in the Scottish
Heart Health Study (Lowe et al, 1988). We also prospec-
tively studied the relative associations of two types of
fibrinogen assay: the routine Clauss assay based on the
clotting rate of fibrinogen (von Clauss, 1957) and a heat
precipitation assay (Millar et al, 1971). Fibrinogen that can
be precipitated by heat has been reported to show a stronger
association with incident coronary heart disease than the
von Clauss assay in the Caerphilly study (Sweetnam et al,
1998).
SUBJECTS AND METHODS
Subjects were selected from two, overlapping, studies: the
first Glasgow MONICA survey (MONICA-1) and the west
Scotland portion of the Scottish Heart Health Study (SHHS).
Both studies used the same questionnaire and clinical
investigations, and each involved selection of an age-/sex-
stratified general population sample from General Practi-
tioners’ lists (Smith et al, 1987). MONICA-1 was a sample of
1262 residents of Glasgow living north of the River Clyde
aged 20–64 years, surveyed in 1986. SHHS was a sample of
10 369 individuals aged 40–59 years, surveyed between
1984 and 1986, with four of the 22 districts included being
considered for this study (Lowe et al, 1988). In total, 1254
subjects were selected, of whom 859 were part of SHHS
only, 195 were part of MONICA-1 only and 200 were
included in both studies.
Participants received questionnaires by post: completed
questionnaires were brought to a clinic session, run by
trained nurses, for checking. The questionnaire included
standard questions about socio-demographic status, med-
ical history and smoking. Rose chest pain questions (Rose
et al, 1977) were also included. Among other investiga-
tions at the clinic, blood pressure measurements were
taken, carbon monoxide in expired air was recorded (as
an objective measure of smoking), and a 12-lead electro-
cardiogram (ECG) and blood sample was extracted. From
the blood sample, lipid measurements were assayed in
serum, as previously described (Smith et al, 1987).
Venous blood was anticoagulated with dry dipotassium
EDTA (final concentration 1Æ5 mg/ml blood) and kept at
4C prior to measurement. Whole blood and plasma
viscosity were measured at 37C in a Coulter-Harkness
capillary viscometer (Lowe et al, 1988). Haematocrit was
measured using a Hawksley microhaematocrit centrifuge
and reader. Fibrinogen was measured in the microhae-
matocrit tube using a heat precipitation method (Millar
et al, 1971). Fibrinogen was also measured as clottable
fibrinogen by the von Clauss assay, in a Coag-A-Mate
(Organon Teknika) automated coagulometer, in citrated
plasma (Woodward et al, 1998).
Follow-up. This article presents results of the mortality
follow-up of all study participants up to June 2001.
Deaths were primarily identified through copies of death
certificates, forwarded by the Scottish National Health
Service Register. Ancillary information was obtained from
enquiries to Scottish health boards and the Information
Table I. Mean values (standard errors) of haematological variables according to sex, smoking status, CVD status at baseline and
whether or not death occurred during follow-up.
Whole blood
viscosity (mPa.s)*
Haematocrit
(%)
Plasma viscosity
(mPa.s)
Fibrinogen-von
Clauss (g/l)*
Fibrinogen-Heat
(g/l)*
Sex
Male (n ¼ 658) 3Æ49 (0Æ019) 45Æ7 (0Æ14) 1Æ33 (0Æ0035) 2Æ10 (0Æ029) 3Æ89 (0Æ035)
Female (n ¼ 596) 3Æ14 (0Æ018) 42Æ2 (0Æ15) 1Æ32 (0Æ0037) 2Æ30 (0Æ034) 3Æ89 (0Æ036)
P-value £ 0Æ0001 £ 0Æ0001 0Æ12 £ 0Æ0001 0Æ95
Smoking
Current (n ¼ 453) 3Æ42 (0Æ023) 44Æ9 (0Æ17) 1Æ33 (0Æ0042) 2Æ37 (0Æ039) 4Æ05 (0Æ043)
Ex (n ¼ 352) 3Æ26 (0Æ025) 43Æ5 (0Æ19) 1Æ32 (0Æ0049) 2Æ17 (0Æ041) 3Æ91 (0Æ048)
Never (n ¼ 439) 3Æ25 (0Æ022) 43Æ3 (0Æ17) 1Æ32 (0Æ0043) 2Æ05 (0Æ035) 3Æ71 (0Æ040)
P-value £ 0Æ0001 0Æ001 0Æ46 £ 0Æ0001 £ 0Æ0001
Baseline CVD
Yes (n ¼ 235) 3Æ37 (0Æ032) 44Æ1 (0Æ24) 1Æ35 (0Æ0059) 2Æ27 (0Æ053) 3Æ96 (0Æ060)
No (n ¼ 1019) 3Æ30 (0Æ015) 43Æ9 (0Æ11) 1Æ32 (0Æ0028) 2Æ18 (0Æ024) 3Æ87 (0Æ028)
P-value 0Æ03 0Æ34 £ 0Æ0001 0Æ14 0Æ19
Death
Yes (n ¼ 184) 3Æ44 (0Æ038) 44Æ5 (0Æ28) 1Æ34 (0Æ0068) 2Æ39 (0Æ066) 4Æ07 (0Æ072)
No (n ¼ 1070) 3Æ29 (0Æ014) 43Æ8 (0Æ11) 1Æ32 (0Æ0028) 2Æ17 (0Æ024) 3Æ86 (0Æ027)
P-value 0Æ0003 0Æ02 0Æ03 0Æ001 0Æ007
*Analysed via log transformation. Point estimates are after back transformation; standard errors are estimated from confidence
intervals after back transformation.
All values adjusted for age and sex.
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and Services Division of the Scottish Common Services
Agency (Tunstall-Pedoe et al, 1997). Death was recorded
as due to a cardiovascular cause if the underlying cause
was coded between 393 and 451 for International
Classification of Disease (ICD) )9 or between I00 and
I99 for ICD-10.
Statistical methods. Mean values for each haematological
variable at baseline were compared between the sexes,
cigarette smoking groups (current/ex/never), those with
and without cardiovascular disease at baseline, and those
who did and did not die during follow-up using general
linear models, adjusting for age and sex. Baseline CVD was
judged positive if the subject had a previous doctor
diagnosis of angina, myocardial infarction (MI) or stroke;
or if they exhibited either angina or MI according to their
ECG or their answers to the Rose questions (Woodward
et al, 1998). Whole blood viscosity and both fibrinogen
variables were log transformed to improve approximations
to normal distributions. To facilitate interpretation, point
estimates of transformed means were back-transformed (by
exponentiation) before presentation. Similarly, standard
errors on the original scale were estimated as half the
width of the 95% confidence interval after back-transfor-
mation, divided by 1Æ96. Haematological variables were
related to continuous major cardiovascular risk factors,
and each other, using Spearman rank correlation coeffi-
cients, again adjusting for age and sex. A P-value of £0Æ05
was considered significant.
Cox proportional hazard regression models were used to
estimate hazard ratios for all-cause mortality associated
with each haematological variable. Values of haematolog-
ical variables were grouped into three equal parts, taking
the lowest third (those below the lowest tertile for their
particular sex) as the reference group. Analyses were
adjusted for age and sex, and additionally for major
cardiovascular risk factors: baseline CVD, smoking status,
carbon monoxide in expired air, systolic and diastolic blood
pressure, triglycerides, and total and high density lipopro-
tein (HDL) cholesterol.
RESULTS
Of the 1254 people studied, 48% were women and the
mean age was 48Æ2 years (standard deviation 8Æ30 years).
During a total of 17 549 person-years of follow-up (for live
subjects, a mean follow-up of 14Æ8 years), 184 (15%) died,
of whom 70 died of cardiovascular causes. Two were lost to
follow-up.
Whole blood viscosity and haematocrit were significantly
(P < 0Æ05) higher in men and von Clauss fibrinogen (but
not heat-precipitated fibrinogen) was significantly higher in
women (Table I). Means of all five haematological variables
(blood and plasma viscosity, haematocrit, von Clauss
fibrinogen and heat-precipitated fibrinogen) were highest
among current smokers and those with prevalent CVD at
baseline, although not always significantly so. All five were
significantly higher among those who subsequently died
during follow-up than among those who survived or were
lost to follow-up. T
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Whole blood viscosity, haematocrit and plasma viscosity
were highly, significantly (P < 0Æ0001) and positively
correlated with systolic and diastolic blood pressure,
triglycerides and serum total cholesterol (Table II). Blood
and plasma viscosity but not haematocrit, were positively
related to age. Blood viscosity and haematocrit, but not
plasma viscosity, were positively related to carbon monox-
ide (tobacco inhalation). None of these three haematological
variables were correlated with HDL cholesterol. Both
fibrinogen variables were strongly, positively correlated
with age, triglycerides, total cholesterol and carbon mon-
oxide, but slightly less strongly, negatively correlated to
HDL cholesterol and were not linearly related to blood
pressure. All five haematological variables were strongly
correlated with each other.
Table III shows hazard ratios for all-cause mortality by
tertiles of haematological variables. Whole-blood viscosity,
haematocrit and both assays of fibrinogen (but not plasma
viscosity) were significantly associated with mortality, after
adjustment for age and sex. After further adjustment for
baseline CVD, smoking, blood pressure, lipids and carbon
monoxide, all hazard ratios were reduced to non-signifi-
cance, with the exception of fibrinogen by the von Clauss
assay [hazard ratio 1Æ49 (95% CI 1Æ01–2Æ21) for upper
tertile versus lower tertile]. Removing baseline CVD from the
adjustment set made virtually no difference to the results.
DISCUSSION
This prospective study observed that blood viscosity and two
of its major determinants (haematocrit and fibrinogen) were
significantly associated with mortality after a follow-up of
13 years, when adjusted only for age and sex. In contrast to
two other prospective studies (Koenig et al, 2000; Lowe
et al, 2000), plasma viscosity was not associated with
incident mortality. Following adjustment for evidence of
baseline CVD, and for classic cardiovascular risk factors
(which were associated with baseline levels of blood
viscosity determinants: Lowe et al, 1988), only fibrinogen
(measured as clottable fibrinogen by the von Clauss assay)
was significantly associated with mortality. These results
are in accordance with the results of the West of Scotland
Coronary Prevention Study in men (Lowe et al, 2000).
Three prospective studies (the present; and Koenig et al,
2000, and Lowe et al, 2000) have now shown that
measures (or determinants) of blood viscosity are associated
with incident mortality. However, the results of the present
study, and of another prospective study in West of Scotland
men (Lowe et al, 2000), show that a major part of this
association is due to the mutual associations of blood
viscosity and its determinants, baseline evidence of CVD,
cardiovascular risk factors and risk of death. In the West of
Scotland, CVD is the leading cause of death, and its risk
Table III. Number (%) of deaths and hazard ratios (95% confidence intervals) for all-
cause mortality by thirds of haematological variables.
Third (male/female
upper boundaries) Deaths (%)
Hazard ratios
Age/sex adjusted Multiple adjusted*
Whole blood viscosity (mPa.s)
1 (3Æ288/2Æ956) 40 (24%) 1 1
2 (3Æ660/3Æ264) 43 (26%) 0Æ96 (0Æ62–1Æ48) 0Æ90 (0Æ58–1Æ42)
3 81 (49%) 1Æ55 (1Æ06–2Æ27) 1Æ29 (0Æ84–1Æ96)
Haematocrit (%)
1 (43/40) 39 (22%) 1 1
2 (46/43) 61 (34%) 1Æ18 (0Æ79–1Æ76) 1Æ10 (0Æ73–1Æ67)
3 79 (44%) 1Æ48 (1Æ01–2Æ17) 1Æ23 (0Æ81–1Æ87)
Plasma viscosity (mPa.s)
1 (1Æ280/1Æ278) 50 (27%) 1 1
2 (1Æ358/1Æ346) 45 (25%) 0Æ72 (0Æ48–1Æ08) 0Æ66 (0Æ43–1Æ01)
3 87 (48%) 1Æ23 (0Æ86–1Æ76) 1Æ07 (0Æ73–1Æ59)
Fibrinogen-von Clauss (g/l)
1 (1Æ88/2Æ05) 38 (21%) 1 1
2 (2Æ38/2Æ63) 53 (30%) 1Æ31 (0Æ86–1Æ98) 1Æ23 (0Æ80–1Æ90)
3 88 (49%) 1Æ78 (1Æ21–2Æ61) 1Æ49 (1Æ01–2Æ21)
Fibrinogen-Heat (g/l)
1 (3Æ55/3Æ54) 47 (27%) 1 1
2 (4Æ30/4Æ28) 45 (26%) 0Æ86 (0Æ57–1Æ29) 0Æ74 (0Æ48–1Æ13)
3 84 (48%) 1Æ45 (1Æ01–2Æ07) 1Æ10 (0Æ75–1Æ62)
*Adjusted for baseline CVD, smoking (current/ex/never), systolic and diastolic blood
pressure, triglycerides, HDL and total cholesterol, and carbon monoxide in expired air.
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factors, such as smoking, are thus the major risk factors for
all-cause mortality. Therefore, the causal role of increased
blood viscosity in increasing the risk of premature mortality
remains to be established, for example by large, randomized
trials of viscosity reduction. A recent large randomized
controlled trial of simvastatin in patients with coronary
disease, other occlusive arterial disease or diabetes has
shown a significant reduction in total mortality, as well as
in cardiovascular events (Heart Protection Study Collabor-
ative Group, 2002). Reduced blood and plasma viscosity by
statins (which lower plasma lipoproteins) is one possible
mechanism for this effect (Lowe et al, 2000).
Clottable fibrinogen, measured using the von Clauss
assay, was independently associated with total mortality in
the present study. This finding is consistent with the
independent association of clottable fibrinogen with total
mortality at the 8-year follow-up of the whole Scottish
Heart Study cohort (Woodward et al, 1998). In the present
study, fibrinogen assayed by a heat-precipitation assay
showed a weaker association with mortality. In contrast,
fibrinogen that could be precipitated by heat was signifi-
cantly associated with mortality in the West of Scotland
Coronary Prevention Study (Lowe et al, 2000), and showed
a stronger association than the von Clauss assay with
incident coronary events in the Caerphilly Study (Sweetnam
et al, 1998). The relative strength of different fibrinogen
assays in the prediction of cardiovascular events and
mortality requires further assessment in large, prospective,
comparative studies.
What are the clinical implications of the association of
fibrinogen levels with mortality? First, this should be
confirmed and quantified in a meta-analysis of all prospect-
ive studies, such as through the ongoing Fibrinogen Studies
Collaboration (Lowe et al, 2002). Second, its causal signi-
ficance should be evaluated in randomized controlled trials
of agents which chronically and selectively lower fibrinogen
levels by 10–20%; however, no such agent is available at
present. Third, lifestyle measures which lower fibrinogen,
such as regular exercise (Wannamethee et al, 2002) and
reduction in smoking habit (Lowe, 2001) should be
encouraged, and indeed recommended, as public health
policy. Fourth, persons with high fibrinogen should be
considered for more intensive treatment for other cardio-
vascular risk factors, particularly lowering of blood pressure
and cholesterol which have recently been shown to be
beneficially lowered among a wide range of patients at a
high risk of CVD (Perindopril Protection Against Recurrent
Stroke Study (PROGRESS) Progress Collaborative Group,
2001; Heart Protection Study Collaborative Group, 2002).
ACKNOWLEDGMENTS
We thank the British Heart Foundation and the Chief
Scientist Office, the Scottish Office, for financial support.
REFERENCES
von Clauss, A. (1957) Geruningsphysiologische schnellmethode zur
bestimmung des fibrinogens. Acta Haematologica, 17, 237–246.
Danesh, J., Collins, R., Peto, R. & Lowe, G.D.O. (2000a) Haemato-
crit, viscosity, erthryocyte sedimentation rate: meta-analyses of
prospective studies of coronary heart disease. European Heart
Journal, 21, 515–520.
Danesh, J., Whincup, P., Walker, M., Lennon, L., Thomson, A.,
Appleby, P., Gallimore, J. & Pepys, M. (2000b) Low grade
inflammation and coronary heart disease: prospective study and
updated meta-analyses. British Medical Journal, 321, 199–204.
Heart Protection Study Collaborative Group (2002) MRC/BHF
Heart Protection Study of cholesterol lowering with simvastatin
in 20536 high-risk individuals: a randomised placebo-controlled
trial. Lancet, 360, 7–22.
Koenig, W., Sund, M., Lowel, H., Doring, A. & Ernst, E. (2000)
Association between plasma viscosity and all-cause mortality:
results from the MONICA-Augsburg Cohort Study 1984–92.
British Journal of Haematology, 109, 453–458.
Lee, A.J., Fowkes, F.G.R., Rattray, A., Rumley, A. & Lowe, G.D.O.
(1996) Haemostatic and rheological factors in intermittent
claudication: the influence of smoking and extent of arterial
disease. British Journal of Haematology, 92, 226–230.
Lee, A.J., Mowbray, P.I., Lowe, G.D.O., Rumley, A., Fowkes, F.G.R.
& Allan, P.L. (1998) Blood viscosity and elevated carotid intima-
media thickness in men and women: the Edinburgh Artery Study.
Circulation, 97, 1467–1473.
Lowe, G.D.O. (1994) Blood rheology, haemostasis and vascular
disease. In: Haemostasis and Thrombosis, edition3rd edn. (ed. by
A.L. Bloom, C.D. Forbes, D.P. Thomas & E.G.D. Tuddenham), pp.
1169–1188. Churchill Livingstone, Edinburgh.
Lowe, G.D.O. (1998) Agents lowering blood viscosity, including
defibrinogenating agents. In: Cardiovascular Thrombosis – Throm-
bocardiology and Thromboneurology, 2nd edn. (ed. by M. Verstra-
ete, V. Fuster & E. Topol) pp. 321–333. Lippincott-Raven,
Philadelphia.
Lowe, G.D.O. (2001) Why do smokers have higher plasma fibrin-
ogen levels than non-smokers? Clinical Science, 101, 209–210.
Lowe, G.D.O., Smith, W.C.S., Tunstall-Pedoe, H.D., Crombie, I.K.,
Lennie, S.E., Anderson, J. & Barbenel, J.C. (1988) Cardiovascular
risk and haemorheology – results from the Scottish Heart Health
Study and the MONICA Project, Glasgow. Clinical Hemorheology,
8, 518–524.
Lowe, G.D.O., Fowkes, F.G.R., Dawes, J., Donnan, P.T., Lennie, S.E.
& Housley, E. (1993) Blood viscosity, fibrinogen and activation of
coagulation and leukocytes in peripheral arterial disease and the
normal population in the Edinburgh Artery Study. Circulation,
87, 1915–1920.
Lowe, G.D.O., Lee, A.J., Rumley, A., Price, J.F. & Fowkes, F.G.R.
(1997) Blood viscosity and risk of cardiovascular events: the
Edinburgh Artery Study. British Journal of Haematology, 96, 168–173.
Lowe, G.D.O., Rumley, A., Norrie, J., Ford, I., Shepherd, J., Cobbe,
S., Macfarlane, P. & Packard, C. on behalf of the West of Scotland
Coronary Prevention Group (2000) Blood rheology, cardiovas-
cular risk factors, and cardiovascular disease: the West of Scot-
land Coronary Prevention Study. Thrombosis and Haemostasis, 84,
553–558.
Lowe, G.D.O., Rumley, A., Whincup, P.H. & Danesh, J. (2002)
Hemostatic and rheological variables and risk of cardiovascular
disease. Seminars in Vascular Medicine, 2, 429–440.
Meade, T., Zuhrie, R., Cook, C. & Cooper, J. on behalf of MRC
General Practice Research Framework (2002) Bezafibrate in men
with lower extremity arterial disease: randomised controlled trial.
British Medical Journal, 325, 1139–1144.
Millar, H.R., Simpson, J.G. & Stalker, A.L. (1971) An evaluation of
the heat precipitation method for plasma fibrinogen estimation.
Journal of Clinical Pathology, 24, 827–830.
Viscosity, Haematocrit, Fibrinogen and Mortality 649
 2003 Blackwell Publishing Ltd, British Journal of Haematology 122: 645–650
Progress Collaborative Group (2001) Randomised trial of a perin-
dopril-based blood-pressure-lowering regimen among 6,105
individuals with previous stroke or transient ischaemic attack.
Lancet, 358, 1033–1041.
Rose, G., McCartney, P. & Reid, D.D. (1977) Self-administration of a
questionnaire on chest pain and intermittent claudication. British
Journal of Preventive and Social Medicine, 31, 42–48.
Smith, F.B., Rumley, A., Lee, A.J., Leng, G.C., Fowkes, F.G.R. &
Lowe, G.D.O. (1998) Haemostatic factors and prediction of
ischaemic heart disease and stroke in claudicants. British Journal
of Haematology, 100, 758–763.
Smith, W.C.S., Crombie, I.K., Tavendale, R., Irving, J.M., Kenicer,
M.B. & Tunstall-Pedoe, H.D. (1987) The Scottish Heart Health
Study: objectives and development of methods. Health Bulletin
(Edinburgh), 45, 211–217.
Sweetnam, P.M., Yarnell, J.W.G., Lowe, G.D.O., Baker, I.A., O’Brien,
J.R., Rumley, A., Etherington, M.D., Whitehead, P.J. & Elwood,
P.C. (1998) The relative power of heat-precipitation nephelo-
metric and clottable (Clauss) fibrinogen in the prediction of
ischaemic heart disease: the Caerphilly and Speedwell studies.
British Journal of Haematology, 100, 582–588.
Tunstall-Pedoe, H., Woodward, M., Tavendale, R., A’Brook, R. &
Mccluskey, M.-K. (1997) Comparison of the prediction by 27
different factors of coronary heart disease and death in men and
women of the Scottish heart health study: cohort study. British
Medical Journal, 315, 722–729.
Wannamethee, S.G., Lowe, G.D.O., Whincup, P.H., Rumley, A.,
Walker, M. & Lennon, L. (2002) Physical activity and hemostatic
and inflammatory variables in elderly men. Circulation, 105,
1785–1790.
Woodward, M., Lowe, G.D.O., Rumley, A., Tunstall-Pedoe, H.,
Philippou, H., Lane, D.A. & Morrison, C.E. (1997) Epidemiology
of coagulation factors, inhibitors and activation markers: the
Third Glasgow MONICA Survey (2) Relationships to cardiovas-
cular risk factors and prevalent cardiovascular disease. British
Journal of Haematology, 97, 785–797.
Woodward, M., Lowe, G.D.O., Rumley, A. & Tunstall-Pedoe, H.
(1998) Fibrinogen as a risk factor for coronary heart disease and
mortality in middle-aged men and women. The Scottish Heart
Health Study. European Heart Journal, 19, 1257–1260.
650 M. Woodward et al
 2003 Blackwell Publishing Ltd, British Journal of Haematology 122: 645–650
